Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Uveal Melanoma 1Prostatic Neoplasms 1Hematologic Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × benzamide × Clear all
NCT04198922 2025-11-05

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
51 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04720417 2025-07-15

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
13 enrolled 13 charts
Dermatologic

Uveal Melanoma

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

University of Washington

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡